Novasep to Expand its HPAPI Capabilities at its France Site
The expansion in Le Mans, France will support growth in clinical and commercial manufacturing.
Novasep announced on May 12, 2021 that it plans to further expand its highly potent active pharmaceutical ingredients (HPAPIs) manufacturing capabilities at its Le Mans, France site.
The expansion is Novasep’s next step in furthering its HPAPI and antibody drug conjugates (ADCs) expertise while continuing to offer its customers contract development and manufacturing capabilities for the production of targeted molecules to treat cancer, the company said in a press release.
“We are pleased to continue our development in strategic markets such as HPAPIs and ADCs, and to participate in the fight against cancer for the benefit of patients,” said Michel Spagnol, chairman and CEO of Novasep, in the press release. “Specifically, this expansion allows us to create more than 30 full-time jobs in Le Mans.”
Source: Novasep
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
